Agenus Inc. (NASDAQ:AGEN) Q3 2019 Earnings Conference Call - Final Transcript
Nov 04, 2019 • 08:30 am ET
Good day, ladies and gentlemen, and welcome to the Agenus Third Quarter 2019 Financial Results and Business Update Conference Call. As a reminder, today's conference is being recorded.
Now, I would like to turn the conference over to Dr. Jennifer Buell, Chief Operating Officer of Agenus. Please go ahead, Dr. Buell.
Thank you, operator. Today's call is being webcast and will be available on our website with our accompanying slide material for replay. Just a reminder, the slides are now live on our webcast and access to a computer you'll be able to view them manually.
Before we start, we would like to remind you that this call will include forward-looking statements, including statements regarding our clinical development and regulatory plans and timelines, as well as timelines for data release and partnership opportunities. These statements are subject to risks and uncertainties and we refer you to our SEC filings for more details on these risks. As a reminder, this call is being recorded for audio broadcast.
Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; Dr. Anna Wijatyk, Head of Clinical Development and Operations; and Christine Klaskin, our Vice President of Finance. I'm going to start this call today by first asking Garo to provide you with the reality of Agenus operationally and in the marketplace. I expect these facts as they are and what we have achieved will be eye opening to you all.
Thank you, Jen. During our last quarterly call, I shared a visual with you, that's the very first slide that you have within your possession. This one speaks to our R&D productivity and the fact that over the last four years in IND filings, we have outpaced other immuno-oncology companies large and small. Also important is the fact that all the INDs that we have filed, all 13 of them so far, represent inventions of Agenus.
During this call, we will update you on the progress we've made with our most advanced programs, our CTLA-4 antibody, Zalifrelimab and our PD-1 antibody Balstilimab, I know these are mouthfuls and I'm just getting used to using them myself. We are targeting commercializing both agents in the first half of 2021, which means we will be filing our BLA or BLAs in 2020.
Our first indication will be second line cervical cancer but, and importantly, we are developing these two antibodies because they are critically important agents to be used in combination with many of our own next-generation antibodies, including by specifics, in combination with our allogeneic cell therapy for which our first IND is on track to be filed this year and also in combination with our cancer vaccines, which include our off-the-shelf phosphorylated antigen vaccine, where we have a highly proprietary position. As you can see from our IND chart, we have generated 13 immuno-oncology agents, which are all in clinical development presently.
We expect that some of the next-generation agents in our pipeline can help expand the market opportunity for our PD-1